Skip to main content

4 Result(s)

within Mourad Tiab Remove this filter Cancer Research Remove this filter

and

  1. Article

    Open Access

    Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

    CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the be...

    Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot… in Nature Medicine (2024)

    Download PDF (3529 KB) View Article

  2. No Access

    Article

    Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

    Arthur Bobin, Maéva Kyheng, Stéphanie Guidez, Cécile Gruchet-Merouze… in Leukemia (2022)

  3. No Access

    Article

    Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

    Jill Corre, Aurore Perrot, Cyrille Hulin, Denis Caillot, Anne-Marie Stoppa… in Leukemia (2021)

  4. Article

    Open Access

    Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

    GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (C...

    Francesc Bosch, Guy Cantin, Agostino Cortelezzi, Wolfgang Knauf, Mourad Tiab… in Leukemia (2020)

    Download PDF (604 KB) View Article